Clinical value of antibodies in inflammatory bowel diseases

Cover Page

Cite item

Full Text

Abstract

Inflammatory bowel disease – IBD (Crohn’s disease – CD, ulcerative colitis – UC) – immune-mediated diseases of the digestive tract of unknown etiology. The basis of the pathogenesis of IBD is a violation of the protective mechanisms of the intestinal barrier as a result of a complex interaction of environmental factors, a genetic predisposition and defects in the activation of the immune response in the lymphoid tissue of the intestinal mucosa. Three groups of antibodies are detected in the sera of IBD patients: autoantibodies, antimicrobial antibodies and antibodies to peptide antigens. In CD, the most useful diagnostic markers are ASCA; in UC patients – pANCA. Antibodies are not among the diagnostic criteria for CD and UC, the diagnosis of which is traditionally made on the basis of a complex of clinical, radiological, endoscopic and histological signs, but can be used as useful additional non-invasive markers for early diagnosis, assessment of clinical phenotypes, prognosis and effectiveness of treatment of these diseases.

About the authors

E. N. Aleksandrova

Loginov Moscow Clinical Research and Practical Center

Email: asfold@mail.ru
ORCID iD: 0000-0003-4074-5907

д.м.н., зав. лаб. клинической иммунологии

Russian Federation, Moscow

A. A. Novikov

Loginov Moscow Clinical Research and Practical Center

Email: asfold@mail.ru
ORCID iD: 0000-0002-2738-2956

д.б.н., вед. науч. сотр. лаб. клинической иммунологии

Russian Federation, Moscow

G. V. Lukina

Loginov Moscow Clinical Research and Practical Center

Email: asfold@mail.ru
ORCID iD: 0000-0001-7958-5926

д.м.н., проф., зав. отд. ревматологии

Russian Federation, Moscow

A. I. Parfenov

Loginov Moscow Clinical Research and Practical Center

Author for correspondence.
Email: asfold@mail.ru
ORCID iD: 0000-0002-9782-4860

д.м.н., проф., зав. отд. патологии кишечника

Russian Federation, Moscow

References

  1. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38 [Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2):8-38 (In Russ.)]. doi: 10.33878/2073-7556-2020-19-2-8-38
  2. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1:6-30 [Ivashkin VT, Shelygin IuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017;1:6-30 (In Russ.)].
  3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307-17. doi: 10.1038/nature10209
  4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24. doi: 10.1038/nature11582
  5. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297
  6. Kayama H, Takeda K. Functions of innate immune cells and commensal bacteria in gut homeostasis. J Biochem. 2016;159(2):141-9. doi: 10.1093/jb/mvv119
  7. Choy MC, Visvanathan K, De Cruz P. An Overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(1):2-13. doi: 10.1097/MIB.0000000000000955
  8. Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017;10(3):155-167
  9. Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-10. doi: 10.3748/wjg.v22.i3.1304
  10. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52(2):171-81. doi: 10.1373/clinchem.2005.058560
  11. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28(3):418-23. doi: 10.1159/000320396
  12. Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 2013;23(1):28-42. doi: 10.11613/bm.2013.006
  13. Kovács M, Müller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873-82. doi: 10.3748/wjg.v20.i17.4873
  14. Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010;122(4):177-85. doi: 10.3810/pgm.2010.07.2184
  15. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18(7):1340-55. doi: 10.1002/ibd.21903
  16. Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14(3):231-45. doi: 10.1016/j.autrev.2014.11.004
  17. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13(12):1561-6. doi: 10.1002/ibd.20226
  18. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008; 67:1004-10. doi: 10.1136/ard.2007.071936
  19. Desplat-Jégo S, Johanet C, Escande A, et al. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13(16):2312-8. doi: 10.3748/wjg.v13.i16.2312
  20. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13(4-5):463-6. doi: 10.1016/j.autrev.2014.01.028
  21. Schulte-Pelkum J, Radice A, Norman GL, et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014;2014:185416. doi: 10.1155/2014/185416
  22. Joossens S, Vermeire S, Van Steen K, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):771-7. doi: 10.1097/00054725-200411000-00012
  23. Zhou G, Song Y, Yang W, et al. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease? Dig Dis. 2016;34(1-2):90-7. doi: 10.1159/000442934
  24. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn’s disease. Autoimmun Rev. 2014;13(4-5):467-71. doi: 10.1016/j.autrev.2014.01.029
  25. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394-403. doi: 10.1136/gut.2006.108043
  26. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-81. doi: 10.1111/j.1572-0241.2007.01652.x
  27. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-34. doi: 10.1038/ajg.2009.79
  28. Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn’s disease: a possible clue to etiology? Inflamm Bowel Dis. 2009;15:714-9. doi: 10.1002/ibd.20831
  29. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367-75. doi: 10.1002/ibd.21179
  30. Somma V, Ababneh H, Ababneh A, et al. The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract. 2013;2013:1-7. doi: 10.1155/2013/683824
  31. Däbritz J, Bonkowski E, Chalk C, et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013;108:1901-10. doi: 10.1038/ajg.2013.360
  32. Mokrowiecka A, Kumor A, Jakubczyk E, et al. The application of Montreal classification in different clinical and serological IBD subtypes. Hepatogastroenterology. 2010;57(101):787-93
  33. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128(7):2020-8. doi: 10.1053/j.gastro.2005.03.046
  34. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126(2):414-24. doi: 10.1053/j.gastro.2003.11.015
  35. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol. 2002; 97:1458-62. doi: 10.1111/j.1572-0241.2002.05689.x
  36. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-8. doi: 10.1002/ibd.20054
  37. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-6. doi: 10.1136/gut.2004.060228

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies